High degree of heterogeneity in Alzheimer's disease progression patterns

PLoS Computational Biology

Volumn 7, Issue 11, 2011, Pages

  Komarova, Natalia L ^a   Thalhauser, Craig J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMERS DISEASE; CLINICAL STUDY; DISEASE PROGRESSION; FOLLOW UP; MEAN VALUES; QUANTITATIVE MEASURES; QUANTITATIVE STUDY; STANDARD DEVIATION; SUB-GROUPS; UP-TIME;

NEURODEGENERATIVE DISEASES;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DEMENTIA; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; FOLLOW UP; FUNCTIONAL ASSESSMENT STAGING; GENETIC HETEROGENEITY; GENETIC VARIABILITY; GLOBAL DETERIORATION SCALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MATHEMATICAL COMPUTING; OUTCOME ASSESSMENT; PROBABILITY; RATING SCALE; AGING; BIOLOGY; CLASSIFICATION; PSYCHOLOGICAL ASPECT; TIME;

AGED; AGED, 80 AND OVER; AGING; ALZHEIMER DISEASE; COHORT STUDIES; COMPUTATIONAL BIOLOGY; DISEASE PROGRESSION; HUMANS; LONGITUDINAL STUDIES; TIME FACTORS;

EID: 81355164216     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1002251     Document Type: Article

References (44)

1. Chui HC, (1987) The significance of clinically defined subgroups of Alzheimer's disease. J Neural Transm (Suppl 24): 57-68.
2. Mann UM, Mohr E, Gearing M, Chase TN, (1992) Heterogeneity in Alzheimer's disease: progression rate segregated by distinct neuropsychological and cerebral metabolic profiles. J Neurol Neurosurg Psychiatry 55: 956-959.
3. Craft S, Teri L, Edland SD, Kukull WA, Schellenberg G, et al. (1998) Accelerated decline in apolipoprotein E-epsilon4 homozygotes with Alzheimer's disease. Neurology 51: 149-153.
4. Farrer LA, Cupples LA, van Duijn CM, Connor-Lacke L, Kiely DK, et al. (1995) Rate of progression of Alzheimer's disease is associated with genetic risk. Arch Neurol 52: 918-923.
5. Murphy GM Jr, Claassen JD, DeVoss JJ, Pascoe N, Taylor J, et al. (2001) Rate of cognitive decline in AD is accelerated by the interleukin-1 alpha-889 *1 allele. Neurology 56: 1595-1597.
6. Jack CR Jr, Shiung MM, Gunter JL, O'Brien PC, Weigand SD, et al. (2004) Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology 62: 591-600.
7. Ridha BH, Barnes J, Bartlett JW, Godbolt A, Pepple T, et al. (2006) Tracking atrophy progression in familial Alzheimer's disease: a serial MRI study. Lancet Neurol 5: 828-834.
8. Sluimer JD, Vrenken H, Blankenstein MA, Fox NC, Scheltens P, et al. (2008) Whole-brain atrophy rate in Alzheimer disease: identifying fast progressors. Neurology 70: 1836-1841.
9. McEvoy LK, Fennema-Notestine C, Roddey JC, Hagler DJ Jr, Holland D, et al. (2009) Alzheimer disease: quantitative structural neuroimaging for detection and prediction of clinical and structural changes in mild cognitive impairment. Radiology 251: 195-205.
10. Nestor SM, Rupsingh R, Borrie M, Smith M, Accomazzi V, et al. (2008) Ventricular enlargement as a possible measure of Alzheimer's disease progression validated using the Alzheimer's disease neuroimaging initiative database. Brain 131: 2443-2454.
11. Mielke MM, Rosenberg PB, Tschanz J, Cook L, Corcoran C, et al. (2007) Vascular factors predict rate of progression in Alzheimer disease. Neurology 69: 1850-1858.
12. Prolo P, Chiappelli F, Angeli A, Dovio A, Perotti P, et al. (2007) Physiologic modulation of natural killer cell activity as an index of Alzheimer's disease progression. Bioinformation 1: 363-366.
13. Morris JC, Edland S, Clark C, Galasko D, Koss E, et al. (1993) The consortium to establish a registry for Alzheimer's disease (CERAD). Part IV. Rates of cognitive change in the longitudinal assessment of probable Alzheimer's disease. Neurology 43: 2457-2465.
14. Storandt M, Grant EA, Miller JP, Morris JC, (2002) Rates of progression in mild cognitive impairment and early Alzheimer's disease. Neurology 59: 1034-1041.
15. Marra C, Silveri MC, Gainotti G, (2000) Predictors of cognitive decline in the early stage of probable Alzheimer's disease. Dement Geriatr Cogn Disord 11: 212-218.
16. Bhargava D, Weiner MF, Hynan LS, Diaz-Arrastia R, Lipton AM, (2006) Vascular disease and risk factors, rate of progression, and survival in Alzheimer's disease. J Geriatr Psychiatry Neurol 19: 78-82.
17. Mann UM, Mohr E, Chase TN, (1989) Rapidly progressive Alzheimer's disease. Lancet 2: 799.
18. Mohr E, Mann UM, Chase TN, (1990) Subgroups in Alzheimer's disease: fact or fiction? Psychiatr J Univ Ott 15: 203-206.
19. Suh GH, Ju YS, Yeon BK, Shah A, (2004) A longitudinal study of Alzheimer's disease: rates of cognitive and functional decline. Int J Geriatr Psychiatry 19: 817-824.
20. Reisberg B, Ferris SH, de Leon MJ, Crook T, (1982) The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry 139: 1136-1139.
21. Reisberg B, (1988) Functional assessment staging (FAST). Psychopharmacol Bull 24: 653-659.
22. Sclan SG, Reisberg B, (1992) Functional assessment staging (FAST) in Alzheimer's disease: reliability, validity, and ordinality. Int Psychogeriatr 4 (Suppl 1): 55-69.
23. Reisberg B, Ferris SH, (1988) Brief Cognitive Rating Scale (BCRS). Psychopharmacol Bull 24: 629-636.
24. Sabbagh MN, Cooper K, DeLange J, Stoehr JD, Thind K, et al. (2010) Functional, global and cognitive decline correlates to accumulation of Alzheimer's pathology in MCI and AD. Curr Alzheimer Res 7: 280-286.
25. Auer S, Reisberg B, (1997) The GDS/FAST staging system. Int Psychogeriatr 9 (Suppl 1): 167-171.
26. Reisberg B, Ferris SH, Franssen EH, Shulman E, Monteiro I, et al. (1996) Mortality and temporal course of probable Alzheimer's disease: a 5-year prospective study. Int Psychogeriatr 8: 291-311.
27. Reisberg B, (1986) Dementia: a systematic approach to identifying reversible causes. Geriatrics 41: 30-46.
28. Ritchie K, Touchon J, (1992) Heterogeneity in senile dementia of the Alzheimer type: individual differences, progressive deterioration or clinical sub-types? J Clin Epidemiol 45: 1391-1398.
29. Mayeux R, Stern Y, Spanton S, (1985) Heterogeneity in dementia of the Alzheimer type: evidence of subgroups. Neurology 35: 453-461.
30. Friedland RP, Koss E, Haxby JV, Grady CL, Luxenberg J, et al. (1988) NIH conference. Alzheimer disease: clinical and biological heterogeneity. Ann Intern Med 109: 298-311.
31. Knesevich JW, Toro FR, Morris JC, LaBarge E, (1985) Aphasia, family history, and the longitudinal course of senile dementia of the Alzheimer type. Psychiatry Res 14: 255-263.
32. Doody RS, Pavlik V, Massman P, Rountree S, Darby E, et al. (2010) Predicting progression of Alzheimer's disease. Alzheimers Res Ther 2: 2.
33. Thalhauser CJ, Komarova NL, (2011) Alzheimer's disease: rapid and slow progression. Proceedings of the Royal Society Interface in press.
34. van der Vlies AE, Verwey NA, Bouwman FH, Blankenstein MA, Klein M, et al. (2009) CSF biomarkers in relationship to cognitive profiles in Alzheimer disease. Neurology 72: 1056-1061.
35. Kester MI, van der Vlies AE, Blankenstein MA, Pijnenburg YA, van Elk EJ, et al. (2009) CSF biomarkers predict rate of cognitive decline in Alzheimer disease. Neurology 73: 1353-1358.
36. Smits LL, Liedorp M, Koene T, Roos-Reuling IE, Lemstra AW, et al. (2011) EEG abnormalities are associated with different cognitive profiles in Alzheimer's disease. Dement Geriatr Cogn Disord 31: 1-6.
37. Cruchaga C, Kauwe JS, Mayo K, Spiegel N, Bertelsen S, et al. (2010) SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer's disease. PLoS Genet 6: e1001101.
38. Singer J, Willett J, (2003) Applied Longitudinal data analysis: modeling change and event occurrence. New York Oxford University Press.
39. Fitzmaurice G, Davidian M, Verbeke G, Molenberghs G, eds. (2009) Longitudinal data analysis. Boca Raton Chapman & Hall/CRC.
40. Molenberghs G, Verbeke G, (2001) A review on linear mixed models for lon- gitudinal data, possibly subject to dropout. Stat Modelling 1: 235-269.
41. Brookmeyer R, Corrada MM, Curriero FC, Kawas C, (2002) Survival following a diagnosis of Alzheimer disease. Arch Neurol 59: 1764-1767.
42. Turnbull BW, (1976) The empirical distribution function with arbitrarily grouped, censored and truncated data. J R Stat Soc Series B Stat Methodol 38: 290-295.
43. De Gruttola V, Lagakos SW, (1989) Analysis of doubly-censored survival data, with application to AIDS. Biometrics 45: 1-11.
44. Gomez G, Lagakos SW, (1994) Estimation of the infection time and latency distribution of AIDS with doubly censored data. Biometrics 50: 204-212.